Introduction

Teething represents a significant developmental milestone in infants, occurring across a predictable timeline from approximately 6 months through 30 months of age. While developmental eruption itself is physiologic and not inherently pathologic, the associated discomfort during active eruption creates legitimate parental concern and clinical consultation requests. Pediatric dentists encounter teething-related concerns in nearly every infant preventive visit, making accurate assessment, symptom differentiation, and evidence-based management recommendations essential skills. This article reviews the clinical features of normal teething, distinguishes teething symptoms from other pathology, and synthesizes current evidence regarding safe, effective comfort measures within the regulatory framework established by the FDA.

Primary Dentition Eruption Timeline

The primary dentition erupts in a largely predictable sequence, though individual variation of 6 months in either direction remains normal. Eruption typically follows a pattern where central incisors emerge first, followed by lateral incisors, canines, first molars, and finally second molars. The mandibular arch generally precedes the maxillary arch by several months.

Eruption typically initiates around 6 months of age with the mandibular central incisors. By 12 months, infants commonly display 4-8 primary teeth. By 18 months, approximately 12-16 primary teeth have erupted. Complete primary dentition, comprising 20 primary teeth (10 maxillary and 10 mandibular), is typically established by 30 months, though emergence can extend to 36 months in normal variation.

The eruption process involves resorption of overlying alveolar bone and gingival tissue, activation of osteoclasts at the follicle apex, and pressure-driven migration occlusally. This inflammatory cascade, while necessary for normal development, produces tissue inflammation, localized edema, and nociceptor activation that explains the characteristic symptoms parents observe.

Clinical Manifestations of Teething

Active teething symptoms occur when the primary tooth crown begins its final migration toward occlusal surfaces. Localized gingival inflammation, edema, and slight erythema at the site of erupting tooth characterize the clinical presentation. Parents report observation of localized swelling 2-3 weeks before tooth emergence, followed by rapid reduction in symptoms once the cusp penetrates the gingival margin.

Systemic symptoms frequently attributed to teething require critical differentiation. While drooling, increased hand-to-mouth behavior, gingival inflammation, and mild sleep disruption correlate with active eruption, fever above 38.5°C, diarrhea, vomiting, and significant systemic illness should prompt evaluation for alternative etiologies. Multiple research studies have demonstrated that fever and significant gastrointestinal symptoms occur at similar rates in non-teething infants, indicating that attribution of systemic illness to teething represents potential missed diagnosis of infections or other pathology.

Localized symptoms include firm pressure sensation on erupting surfaces, gingival swelling that may be firm (if the erupting tooth is close to piercing gingiva) or softer and more boggy (if eruption is earlier in its phase), slight temperature elevation at the affected site compared to surrounding tissue, and drooling that may lead to perioral dermatitis if not managed with frequent gentle cleansing.

Safe Cold Pressure Strategies

Cold application provides topical anesthesia through A-delta fiber stimulation and reduces inflammatory mediators at affected sites. Chilled (not frozen) teething rings fabricated from food-grade silicone provide safe mechanical stimulation combined with cold exposure. Rings should be refrigerated to 4-10°C rather than frozen; frozen rings risk tissue damage and may be too firm for safe use.

Parents should avoid teething rings or products stored in freezers, as temperatures below 0°C can cause localized tissue injury in the sensitive oral mucosa. Supervision is essential—teething rings should never be left unattended, as they present choking or entanglement hazards. Clean teething rings with warm water and mild soap before each use to prevent bacterial contamination.

Gum massage using clean, dampened gauze or a clean fingertip provides gentle pressure that stimulates mechanoreceptors, competing with nociceptive input. Parents can perform circular massage motions over affected gingival surfaces for 1-2 minutes, repeating several times daily. This technique requires minimal cost, involves no pharmacologic agents, and provides tactile contact valued by infants during discomfort.

Systemic Pharmacologic Management

Acetaminophen remains the first-line systemic analgesic for teething discomfort in infants. Dosing follows weight-based protocols: 10-15 mg/kg per dose, administered every 4-6 hours as needed, with maximum daily doses not exceeding 5 doses per day (approximately 50-75 mg/kg daily). For a 6-month-old infant weighing approximately 7-8 kg, this represents 70-120 mg per dose. Suspension formulations typically contain 160 mg/5 mL, making 2-3 mL the standard infant dose.

Ibuprofen has been established as safe for use in infants older than 6 months, with superior anti-inflammatory properties compared to acetaminophen alone. The recommended dose is 5-10 mg/kg every 6-8 hours, with maximum daily dosing not exceeding 40 mg/kg. A 9-month-old infant at 8-9 kg would receive approximately 40-90 mg per dose. Ibuprofen suspension typically contains 100 mg/5 mL, translating to 2-4 mL per dose.

Critical safety considerations include never exceeding labeled maximum daily doses, avoiding overlapping doses of acetaminophen and ibuprofen, and verifying accurate weight-based dosing with parents before administration recommendations. Parents frequently use over-the-counter infant formulations without regard to concentration differences, risking either subtherapeutic or toxic dosing. Clinicians should reinforce that dosing products formulated for older children (which contain higher concentrations) with infant-weight-based calculations results in underdosing.

FDA Warnings on Topical Numbing Agents

The FDA issued significant regulatory warnings regarding benzocaine-containing topical anesthetics in 2014 and reinforced these warnings in subsequent years. Benzocaine products marketed specifically for teething—including over-the-counter gels, ointments, and liquid products—carry black box warnings due to documented cases of methemoglobinemia, a potentially fatal condition where hemoglobin is oxidized to a form incapable of oxygen transport.

Methemoglobinemia risk increases substantially in infants under 6 months and in those with underlying hemoglobinopathies. Case reports documented infants developing cyanosis, reduced oxygen saturation, and cardiovascular collapse following application of benzocaine-containing teething products. The FDA recommends avoiding benzocaine entirely in pediatric patients under 2 years and exercising extreme caution in older children.

Similar warnings apply to products containing belladonna or atropine alkaloids, which have been documented to cause anti-cholinergic toxicity in infants. These agents are no longer recommended and should be actively discouraged when parents present with such products. Homeopathic teething tablets containing belladonna have resulted in documented toxicity and warrant parent education regarding safety profiles.

Salicylates and aspirin-containing products are contraindicated in children under 18 years due to Reye syndrome risk, regardless of the indication. Products claiming to contain "natural" or "homeopathic" active ingredients require scrutiny, as regulation of such products varies and contamination with pharmaceutical agents or excessive concentrations has been documented in FDA inspections.

When to Refer for Pediatric Evaluation

While teething discomfort is developmentally normal, several presentations warrant referral for pediatric medical evaluation. Fever exceeding 38.5°C (101.3°F) should not be attributed to teething; pneumococcal vaccination status, upper respiratory infection signs, otitis media, urinary tract symptoms, and gastrointestinal findings should be systematically evaluated. Significant diarrhea (more than 2-3 loose stools daily), vomiting, or refusal to feed suggests alternative diagnosis. Lethargy, rash, or signs of dehydration warrant immediate pediatric evaluation.

In the dental setting, eruption delays where no primary teeth have appeared by 18 months, significantly asymmetric eruption patterns, or ectopic eruption positions may indicate systemic factors (hypophosphatasia, ectodermal dysplasia, metabolic disturbances) or localized pathology requiring orthodontic assessment. Severe gingival swelling extending beyond the immediate eruption site, purulent drainage, or fluctuance suggests localized infection rather than developmental inflammation.

Clinical Documentation and Parent Education

Accurate assessment of teething symptoms should be documented in the clinical record, noting which teeth are erupting, degree of gingival inflammation (using descriptive terms such as minimal, moderate, or severe), presence of fever (specifically excluding attribution of fever to teething without documentation of alternative diagnosis consideration), and any systemic symptoms. Documentation serves to establish baseline findings and prevent retrospective erroneous attribution of intercurrent illnesses to teething.

Parent education should emphasize normal eruption timeline variation, distinguish developmental symptoms from systemic illness requiring medical evaluation, demonstrate safe gum massage techniques, review appropriate pharmacologic dosing with dose calculation for the infant's current weight, and specifically address teething product safety, including warnings regarding benzocaine, belladonna-containing products, and inappropriate use of frozen teethers.

Conclusion

Teething management reflects the intersection of developmental physiology and evidence-based symptom management. Pediatric dentists occupy a unique position to accurately assess eruption status, differentiate teething symptoms from systemic illness, guide parents toward safe comfort measures (cold pressure, gum massage), ensure appropriate analgesic dosing, and provide critical safety education regarding FDA-regulated topical agents and unproven alternative products. This comprehensive approach maximizes infant comfort while protecting systemic health and establishes the foundation for ongoing preventive pediatric dental care.